AHA: PREVENT Risk Calculator Estimates Risk for Cardiovascular Disease
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 13, 2023 -- The Predicting Risk of Cardiovascular Disease (CVD) Events (PREVENT) risk calculator estimates the risk for CVD, including heart failure, according to a methods paper and accompanying scientific statement published online Nov. 10 in Circulation to coincide with the American Heart Association Scientific Sessions 2023, held from Nov. 11 to 13 in Philadelphia.
Sadiya S. Khan, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues developed and validated the PREVENT equations among U.S. adults aged 30 to 79 years without known CVD. The derivation sample included individual-level participant data from 25 datasets with 3,281,919 participants; external validation was performed in 3,330,085 participants from 21 additional datasets. Predictors included traditional risk factors and estimated glomerular filtration rate (eGFR). The researchers identified 211,515 incident total CVD events during a mean follow-up of 4.8 years. In external validation for CVD, the median C-statistics were 0.794 and 0.757 in female and male participants, respectively. For men and women, the calibration curves were 1.03 and 0.94, respectively. Similar estimates for discrimination and calibration were seen for atherosclerotic CVD- and heart failure-specific models.
In a scientific statement, Khan and colleagues discuss the clinical implications of the PREVENT equations. The authors note that use of the equations allows 10- and 30-year risk estimates for total CVD (composite of atherosclerotic CVD and heart failure). The sex-specific risk equations include eGFR as a predictor and remove race from risk prediction estimates.
"The PREVENT equations are a critical first step toward including cardiovascular-kidney-metabolic health and social factors in risk prediction for CVD," Khan said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Implantable Continuous Flow Device Feasible for Small Children With Severe Systolic Heart Failure
FRIDAY, May 10, 2024 -- The Jarvik 2015 left ventricular assist device (LVAD) seems promising as an implantable continuous flow device for small children with severe systolic...
Cardiovascular, Kidney, and Metabolic Syndrome Highly Prevalent in the U.S.
FRIDAY, May 10, 2024 -- Cardiovascular, kidney, and metabolic (CKM) syndrome is highly prevalent in the United States, with more than 90 percent of adults meeting the criteria for...
Early Dapagliflozin Does Not Impact Diuretic Efficiency in Acute Heart Failure
THURSDAY, May 9, 2024 -- For patients with acute heart failure (AHF), early initiation of dapagliflozin does not affect diuretic efficiency, according to a study published in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.